The global breast cancer liquid biopsy market size was valued at USD 1.26 billion in 2025 and is projected to grow from USD 1.37 billion in 2026 to USD 2.60 billion by 2034, registering a CAGR of 8.4% during the forecast period from 2026 to 2034. North America dominated the breast cancer liquid biopsy market with a market share of 42.5% in 2025.
Breast cancer liquid biopsy is a minimally invasive testing method that analyzes blood or other body fluids to detect cancer-related materials such as circulating tumor cells and tumor DNA. It can help with early detection, treatment selection, and monitoring of disease progression or recurrence. Demand is growing due to advances in precision medicine, improved testing technologies, and the need for less invasive cancer diagnostic methods.
Download a Free Sample To learn more about this report,
Integration of AI with Circulating Tumor DNA Analysis
Breast cancer liquid biopsy market analysis shows that artificial intelligence is shifting circulating tumor DNA analysis toward faster and more precise interpretation of complex molecular data. AI algorithms can identify mutation patterns and low-frequency ctDNA signals within large sequencing datasets, supporting earlier detection of treatment response and disease progression. Machine-learning models trained on ctDNA profiles are also being investigated for distinguishing molecular changes associated with recurrence and therapy resistance.
Adoption of Multi-Analyte Liquid Biopsy Platforms
Breast cancer liquid biopsy platforms are transitioning from single-biomarker testing toward multi-analyte approaches that analyze ctDNA, circulating tumor cells, exosomes, and other biomarkers from a single blood sample. Combined biomarker analysis can provide a broader molecular view of tumor characteristics and help address the limitations of relying on one analyte alone. For instance, multi-omics liquid biopsy platforms can integrate genomic, epigenomic, and protein-based signals to improve cancer detection and treatment monitoring.
Demand for Minimally Invasive Cancer Monitoring and Advances in Next-Generation Sequencing for Liquid Biopsy Drive Market
Patient and clinician preference for less invasive monitoring creates demand for liquid biopsy tests that can assess breast cancer through a blood sample. Compared with repeated tissue biopsies, blood-based testing can support serial monitoring with less procedural burden for patients. Circulating tumor DNA analysis provides a practical application for tracking molecular changes during treatment and follow-up. Greater need for convenient and repeatable cancer monitoring therefore supports demand for breast cancer liquid biopsy solutions.
Advances in next-generation sequencing improve the supply of liquid biopsy technologies capable of detecting and characterizing low levels of tumor-derived genetic material. Higher sequencing sensitivity and broader genomic coverage allow laboratories to identify mutations that may guide treatment selection and disease monitoring. Clinical liquid biopsy tests can use targeted NGS panels to analyze circulating tumor DNA from blood samples. These technological improvements expand the capabilities of liquid biopsy testing and support market growth.
Limited ctDNA Detection Sensitivity and High Liquid Biopsy Testing Costs Restrain Market Expansion
Limited sensitivity in detecting low levels of circulating tumor DNA can make liquid biopsy results less reliable when tumor burden is low or biomarker levels are minimal. This limitation can increase the risk of false-negative results and reduce confidence in liquid biopsy for early detection and disease monitoring. As a result, cautious clinical adoption can restrict Breast Cancer Liquid Biopsy Market growth.
High costs of advanced liquid biopsy testing increase the financial burden associated with sequencing, molecular analysis, specialized equipment, and laboratory processing. These expenses can limit access for patients and healthcare providers, particularly in cost-sensitive healthcare settings. Consequently, lower affordability can slow test adoption and restrict market expansion.
Adoption of Liquid Biopsy for Minimal Residual Disease Detection and Expansion of Breast Cancer Liquid Biopsy in Companion Diagnostics Offers Growth Opportunities
Oncology centers, diagnostic laboratories, and liquid biopsy developers can use blood-based testing to identify molecular signs of residual disease after treatment. Revenue avenues include MRD testing services, laboratory-developed tests, and recurring monitoring programs. Companies such as Guardant Health, Natera, and Personalis are active in MRD and circulating tumor DNA testing.
Pharmaceutical companies, diagnostic developers, and oncology laboratories can use liquid biopsy to identify biomarkers that help match breast cancer patients with targeted therapies. Revenue opportunities include companion diagnostic tests, biomarker testing services, and partnerships with drug developers. Companies such as Foundation Medicine, Guardant Health, and Roche operate in liquid biopsy and companion diagnostic applications.
Complex Biomarker Validation, Clinical Interpretation, and Standardization Challenges Across Liquid Biopsy Platforms
Variations in tumor biology and biomarker profiles make it difficult to establish consistent interpretation across patient groups and testing platforms. Companies require extensive clinical validation to demonstrate clinical utility, which can lengthen development timelines and delay commercialization.
Differences in sample preparation, sequencing methods, biomarker panels, and reporting protocols can lead to inconsistent results between laboratories. This increases validation and quality-control requirements for companies and can slow adoption by healthcare providers.
The circulating cell-free DNA (cfDNA) segment accounted for a share of 45.8% in 2025 due to its high clinical relevance, non-invasive detection capabilities, and increasing use in breast cancer diagnosis and monitoring.
The extracellular vesicles (EVs) segment is expected to grow at a CAGR of 18.14%, driven by their potential to provide tumor-derived biomarkers for early detection, disease monitoring, and treatment response assessment. The circulating tumor cells (CTCs) segment supports market growth through direct detection and characterization of tumor cells in blood samples. The other circulating biomarkers segment contributes through additional biomarkers that support breast cancer detection, monitoring, and treatment assessment.
Request Customizationto receive a tailored report.
The monitoring segment accounted for a share of 29.2% in 2025 due to the growing use of liquid biopsy for tracking disease progression, treatment response, and recurrence in breast cancer patients. Its minimally invasive nature and ability to support repeated testing further strengthen its dominant market position.
The early detection/screening segment is expected to grow at a CAGR of 18.92%, driven by the need for non-invasive cancer detection methods, improved biomarker analysis, and earlier identification of breast cancer. The diagnosis segment supports market growth through non-invasive detection and molecular characterization of breast cancer. The treatment selection segment contributes through biomarker analysis that helps identify suitable therapies for individual patients.
Speak to an Analystto discuss market opportunities.
The North America breast cancer liquid biopsy market accounted for the largest regional share of 42.5% in 2025, supported by advanced healthcare infrastructure, strong adoption of precision oncology, and increasing use of minimally invasive cancer diagnostic technologies.
The U.S. breast cancer liquid biopsy market is expected to benefit from the projected increase in breast cancer cases, with NCI forecasting annual U.S. breast cancer diagnoses to reach 441,000 by 2030, up from 283,000 in 2011, supporting demand for advanced diagnostic and monitoring technologies. The Canada breast cancer liquid biopsy market is expected to benefit from the projected increase in breast cancer cases, with Health Canada projections indicating that annual female breast cancer cases could reach 31,255 by 2028–2032, up from 20,110 in 2003–2007, increasing the need for cancer detection and monitoring technologies.
Unlock Regional Insightsto access country-level data, & regional trends.
The Asia Pacific breast cancer liquid biopsy market is expected to grow at a CAGR of 18.67% during the forecast period, showcasing the fastest-growing regional market, supported by the rising burden of breast cancer, expanding healthcare infrastructure, and growing adoption of advanced molecular diagnostic technologies across the region. The Japan breast cancer liquid biopsy market is expected to benefit from the projected rise in cancer incidence, with Japan’s National Cancer Center estimating 98,800 new breast cancer cases in 2025, supporting demand for advanced diagnostic and monitoring technologies.
The China breast cancer liquid biopsy market is expected to benefit from the projected increase in disease burden, with studies estimating that new breast cancer cases will reach 452,000 by 2030, a 28.3% increase from 2020, supporting demand for advanced cancer detection and monitoring technologies. The South Korea breast cancer liquid biopsy market is expected to benefit from the projected increase in breast cancer burden, with a recent Asia-wide analysis estimating that breast cancer cases in the Republic of Korea could reach 16,111 by 2030, supporting demand for molecular diagnostic and monitoring technologies. The India breast cancer liquid biopsy market is expected to benefit from the continuing burden of breast cancer, with ICMR reporting that breast cancer accounts for 8.2% of cancer cases in India and noting that more than 100,000 new breast cancer patients are estimated to be diagnosed annually, supporting demand for advanced diagnostic technologies.
The Europe breast cancer liquid biopsy market accounted for a regional share of 27.3% in 2025, supported by advanced cancer care infrastructure, strong research capabilities, and growing adoption of minimally invasive diagnostic technologies. The U.K. breast cancer liquid biopsy market is expected to benefit from the projected breast cancer burden, with Cancer Research UK estimating around 70,300 new breast cancer cases annually by 2038–2040, supporting demand for advanced diagnostic and monitoring technologies.
The Germany breast cancer liquid biopsy market is expected to benefit from the projected increase in breast cancer cases, with a cancer-incidence projection estimating 91,200 female breast cancer cases by 2030, up from 80,077 in 2020, supporting demand for advanced cancer detection and monitoring technologies. The France breast cancer liquid biopsy market is expected to benefit from the continued breast cancer burden, with the French National Cancer Institute reporting 61,214 new breast cancer cases in 2023 and noting that incidence has remained broadly stable, while France’s 2026–2030 cancer-control roadmap continues to prioritize cancer prevention, screening, and care.
The Middle East & Africa breast cancer liquid biopsy market is expected to grow at a CAGR of 14.35% during the forecast period, showcasing the fastest-growing regional market, supported by the rising breast cancer burden, improving diagnostic infrastructure, and increasing adoption of minimally invasive testing technologies across the region.
The UAE breast cancer liquid biopsy market is expected to benefit from the continued breast cancer burden, with IARC reporting breast cancer as the most prevalent cancer among women globally and identifying the need for earlier diagnosis and improved access to cancer management, supporting demand for minimally invasive diagnostic technologies. The Africa breast cancer liquid biopsy market is expected to benefit from the projected rise in breast cancer cases, with WHO estimating that new breast cancer cases in the African Region will increase by 85.7% by 2040 from 2020 levels, while breast cancer deaths are projected to rise by 89%, strengthening the need for earlier diagnosis and monitoring technologies.
The breast cancer liquid biopsy market is moderately fragmented, with competition involving established diagnostic companies, biotechnology firms, molecular testing providers, pharmaceutical companies, and specialized liquid biopsy technology developers. The leading players in the Breast Cancer Liquid Biopsy Market include QIAGEN, Hoffmann-La Roche Ltd., Illumina, Thermo Fisher Scientific Inc., and Guardant Health Inc., collectively accounting for approximately 25–28% of the market.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, competitive dynamics, and market opportunities. Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.
Bacteriophage Market Size, Share, Growth, Analysis, 2034
Epigenetics Market Size, Share, Growth, Analysis, Report, 2034
Biobanking Market Size, Share, Growth, 2034
Cell Therapy Manufacturing Market Size, Share, Growth, 2034
Clinical Oncology Next Generation Sequencing Market Size, 2034
Autoimmune Disease Diagnostics Market Size, Share, Growth, 2034
We are featured on:
sales@straitsresearch.com